Purpose: Immunotherapy has emerged as a novel therapy, while many patients are refractory. Although, several biomarkers have been identified as predictive biomarkers for immunotherapy, such as tumor specific genes, PD-1/PD-L1, tumor mutation burn (TMB), and microsatellite instability (MSI), results remain unsatisfactory. The aim of this study is to evaluate the value of LRP2 mutations in predicating cancer immunotherapy. Methods: We investigated the characteristics of low-density lipoprotein receptor-related protein 2 (LRP2) mutation in the cancer genome atlas (TCGA) and explored the potential association of LRP2 mutations with immunotherapy. Characteristics of LRP2 mutations in 33 cancer types were analyzed using large-scale public data. The association of LRP2 mutations with immune cell infiltration and immunotherapy efficacy was evaluated. Finally, a LPR2 mutation signature (LMS) was developed and validated by TCGA-UCEC and pan-cancer cohorts. Furthermore, we demonstrated the predictive power of LMS score in independent immunotherapy cohorts by performing a meta-analysis. Results: Our results revealed that patients with LRP2 mutant had higher TMB and MSI compared with patients without LRP2 mutations. LRP2 mutations were associated with high levels of immune cells infiltration, immune-related genes expression and enrichment of immune related signaling pathways. Importantly, LRP2-mutated patients had a long overall survival (OS) after immunotherapy. In the endometrial cancer (EC) cohort, we found that patients with LRP2 mutations belonged to the POLE and MSI-H type and had a better prognosis. Finally, we developed a LRP2 mutations signature (LMS), that was significantly associated with prognosis in patients receiving immunotherapy. Conclusion: These results indicated that LRP2 mutations can serve as a biomarker for personalized tumor immunotherapy. Importantly, LMS is a potential predictor of patients’ prognosis after immunotherapy.
16 September 2022 in International Urogynecology Journal
Purpose: Congenital cervical and vaginal aplasia is a rare condition that has a great impact on patients physically and psychologically. The present study was designed to assess depressive symptoms related to congenital cervical vaginal aplasia and provide a scientific basis for formulating psychological intervention measures. Patients and Methods: This was a cross-sectional study of forty-six patients who were diagnosed with congenital cervical and vaginal aplasia and underwent cervicovaginal reconstruction surgery between January 2018 and December 2020. Patients were required to complete a demographic questionnaire, the Patient Health Questionnaire-9 (PHQ-9), the Generalized Anxiety Disorder-7 (GAD-7), and the Symptom Checklist-90 (SCL-90). When patients had sexual activity, their sexual function was evaluated by the Female Sexual Function Index (FSFI) questionnaire. The main outcome was the depressive symptoms screened by PHQ-9, and the factors affecting depressive symptoms were analyzed. Quantitative and categorical variables were compared using Student’s t-test and chi-squared test, respectively. Results: Of all patients diagnosed with congenital cervical and vaginal aplasia, 58.7% (27/46) presented moderate to severe depressive symptoms. Some factors were related to the patient’s depressive symptoms, such as age, parental attitudes, family disharmony, being teased by peers, sexual dysfunction, fertility anxiety, and feeling uncomfortable while wearing the vaginal mold. Conclusion: Half of patients with congenital cervical and vaginal aplasia have depressive symptoms. These findings stress that psychotherapy should be regarded as an independent treatment for patients with congenital cervical and vaginal aplasia.
1 May 2020 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Surgical management for cervical malformation remains as the main therapeutic challenge for gynecologists. A theoretical alternative is to generate a bioengineered uterus cervix, which requires scaffold structure and appropriate cellular constituents. Here, human uterine cervical tissue was decellularized with detergents to produce an acellular scaffold that retained extracellular matrix (ECM), characterized through histochemical studies and DNA assessments. Recellularized scaffold was then established by decellularized scaffold reseeding with adipose-derived stem cells (ADSCs) isolated from rats. We tested these bioengineering samples in a rat model of partial cervical defect and found that recellularized scaffold improved regeneration abilities of the uterine cervix, promoted better vascularization, and achieved positive pregnancy outcomes. These results suggest that decellularized human uterine cervical scaffold combined with ADSCs could be used for uterine cervical regeneration and provide insights into treatments for cervical malformation.